Active
Small Business
Overview
- Legal name
- MAPP BIOPHARMACEUTICAL, INC.
- Registered location
- SAN DIEGO, CA, USA
- Website
- Company website ↗
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- Latest award activity
- Aug 12, 2026
Read company summary
MAPP BIOPHARMACEUTICAL, INC. is associated with UEI M9V9QTHR1H28 and CAGE 417U0 in public federal records. AcornBids currently links 13 prime awards totaling $550.0M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology); Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Its public SAM.gov registration lists SAN DIEGO, CA, USA.
At a glance
Lifetime prime obligations$550.0M
Prime awards13
Awards with future end dates4
Top-agency concentration
Not available
Why this customer concentration
Detailed agency totals are not available in this stored profile.
Largest positive coded-agency total ÷ all positive coded-agency totals × 100
Missing data is shown as unavailable.
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Sep 28, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- MAPP BIOPHARMACEUTICAL, INC.
- UEI
- M9V9QTHR1H28
- CAGE
- 417U0
- Registered address
- 4921 DIRECTORS PL, SAN DIEGO, CA, 92121, USA
- Registration status
- Active
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- SAM activation
- Mar 24, 2026
- Initial registration
- Jul 19, 2005
- Entity start
- Jul 9, 2003
- SAM updated
- Mar 24, 2026
- Registration expires
- Mar 20, 2027
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Federal award analysis
Net transaction obligations by federal fiscal period.
Transaction history is not available in the loaded data. Annual funding is not estimated from current award totals.
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75A50124C00003DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | Department of Health and Human Services | $5.6M | Mar 20, 2024 | Dec 31, 2032 |
| 75A50122C00061PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | Department of Health and Human Services | $220.6M | Sep 30, 2022 | Sep 29, 2032 |
| HHSO100201600021CMAPP EAP - IGF::CL::IGF FOR OTHER FUNCTIONSEXPANDED ACCESS PROTOCOL FOR ZMAPP | Department of Health and Human Services | $28.9M | Jun 27, 2016 | Dec 31, 2027 |
| 75A50122C00076THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR… | Department of Health and Human Services | $110.9M | Sep 28, 2022 | Jul 31, 2036 |
| 75A50118C00024IGF::OT::IGF | Department of Health and Human Services | $56.7M | Sep 25, 2018 | Dec 31, 2024 |
| 75A50119D00018MAPP 2019 CONTRACT | Department of Health and Human Services | $37.5M | Jun 3, 2019 | Not available |
| HHSO100201700023CIGF::OT::IGF | Department of Health and Human Services | $7.5M | Sep 13, 2017 | Jun 30, 2022 |
| 75A50120C00198DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | Department of Health and Human Services | $16.4M | Sep 30, 2020 | Jun 30, 2026 |
| HT942626FE011PROCUREMENT OF HUMAN DERIVED MONOCLONAL ANTIBODIES AND ANTIGENS | Department of Defense | $20.5K | Feb 6, 2026 | Apr 24, 2026 |
| HT942525F0237ANTIBODY & ANTIGEN SUPPLY | Department of Defense | $110.5K | Jun 6, 2025 | Dec 4, 2025 |
Upcoming positioning windows
Modeled recompete windows are estimates, not announced solicitations or guarantees.
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Mar 24, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Jul 19, 2005 |
| Entity start | Jul 9, 2003 |
Registration classifications: Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 325413 — In-Vitro Diagnostic Substance Manufacturing | Not reported |
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| LARRY ZEITLIN | Government business | Contact method not published | SAM registration | Not available |
| LARRY ZEITLIN | Alternate government business | Contact method not published | SAM registration | Not available |
| LARRY ZEITLIN | Electronic business | Contact method not published | SAM registration | Not available |
| LARRY ZEITLIN | Alternate electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 325413 — In-Vitro Diagnostic Substance Manufacturing
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
276 awards
68 awards
56 awards
50 awards
47 awards
46 awards
39 awards
30 awards
About MAPP BIOPHARMACEUTICAL, INC.
What products and services appear in its federal awards?
Recorded award industries: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); 541711; 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
Recorded products and services: 6505 — Drugs and Biologicals; AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT; AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH.
Examples from recent award records:
- DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS
- PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES
These records describe federal award work, not every company capability. Review the award evidence.
Where is the company registered?
4921 DIRECTORS PL, SAN DIEGO, California 92121, United States
Registered location from SAM.gov; award performance locations may differ.
What is its primary registered industry?
541714 — Research and Development in Biotechnology (except Nanobiotechnology).
Primary SAM.gov NAICS classification.
Which federal agencies are represented in its awards?
Department of Health and Human Services; Department of Defense.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
No official subaward rows are loaded, so Acorn does not claim known teaming relationships.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit